{"success":true,"data":{"pressRelease":{"id":"53366","rtpr_id":"nPn3tqsrDa","ticker":"MMED","exchange":"NASDAQ","all_tickers":["MMED"],"title":"MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook","author":"PR Newswire","published_at":"2026-06-03T10:46:00.047Z","article_body":"MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook\n\nPR Newswire\n\nNORTHRIDGE, Calif., June 3, 2026\n\n * Continued momentum in Q4, with net sales of $837 million growing 16% as\nreported and 9% organic year-over-year\n * Record annual net sales performance surpasses $3B for first time, growing 14%\nas reported and 8% organic\n * Advanced global pipeline ahead of schedule with FDA clearance for MiniMed\nFlex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDI\nNORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a\nglobal leader in diabetes technology, today reported financial results for its\nfourth quarter and full fiscal year ended April 24, 2026.\n\n(https://mma.prnewswire.com/media/2993964/MiniMed_Earnings_Presentation_FY26Q4.pdf?p=original)\n\n\"MiniMed delivered a strong finish to our fiscal year, driven by strength in\ninternational markets and continued global adoption of the MiniMed™ 780G\nsystem,\" said MiniMed Chief Executive Officer Que Dallara. \"Looking ahead,\nwe're confident that our launches of MiniMed Flex™ and MiniMed Go™ will\nsupport long-term growth acceleration and value creation.\"\n\nFiscal Fourth Quarter Results\n\n * Continued momentum through the second half of the fiscal year 2026, driven by\nSimplera™ and Instinct sensor, made by Abbott, CGM launches\n * Worldwide net sales of $837 million grew 15.6% as reported and 8.7% organic\n* International net sales of $599 million grew 22.4% as reported and 12.2%\norganic, driven by Simplera capacity expansion; International New Pumps Sold\n(NPS) increased high-single digits sequentially\n * U.S. net sales of $238 million grew 1.5% as reported and organic, as early FDA\nclearance of MiniMed™ Flex shifted demand of customers who preferred to\nwait for the new system. Flex is on track to launch this month. U.S. momentum\ncontinued with NPS increasing mid-single digits sequentially driven by new\nsensor launches\n * Worldwide NPS of ~42,000, an increase of 7.4% quarter-over-quarter\n * Worldwide CGM Attachment Rate of 68%, an increase of 100 bps\nquarter-over-quarter\nFiscal Year 2026 Results\n\n * Worldwide net sales of $3.102 billion grew 14.2% as reported and 8.0% organic\n* International net sales of $2.185 billion grew 20.6% as reported and 11.2%\norganic\n * U.S. net sales of $917 million grew 1.5% as reported and organic\n * Worldwide New Pumps Sold of ~145,000 were unchanged year-over-year\n * Worldwide CGM Attachment Rate of 66%, an increase of 700 bps year-over-year\n * Ended FY26 with worldwide pump users of ~659,000\nFiscal Year 2026 Highlights\n\n * Commercial launches of MiniMed™ 780G system with Instinct sensor and\nSimplera Sync™ sensor in the U.S.; MiniMed Go™ Smart MDI system in EMEA\n * U.S. FDA clearances of MiniMed Flex™ next-generation insulin pump and\nMiniMed Go™ Smart MDI system\n * CE Marks received for MiniMed™ 780G system with Instinct sensor, and\nMiniMed™ 780G system for ages 2 and older, pregnant women, and type 2\ndiabetes\n * U.S. pharmacy formulary access for MiniMed™ 780G system and Medicare access\nfor MiniMed™ 780G system with Instinct sensor\n * Started U.S. pivotal study for Vivera™ third generation fully closed loop\nalgorithm for type 1 and type 2 diabetes\nNew Announcements Made Today\n\n * U.S. MiniMed Go™ was launched last week\n * MiniMed™ 780G with Instinct will launch in Europe later this month\n * MiniMed Flex™ pre-orders in the U.S. started this week and expect to begin\nshipping later this month\n * Extension today to Abbott partnership to commercialize dual glucose-ketone\nsensors designed to integrate exclusively with our MiniMed smart dosing\nsystems\nFiscal Year 2027 Outlook\nFor the fiscal year 2027 ending April 30, 2027, MiniMed expects:\n\n * Organic revenue growth of approximately 10%, which includes a 1.0 to 1.5%\nexpected benefit from the extra week in FY27.\n * Adjusted EBITDA margin of approximately 16%.\nConference Call Details\nMiniMed will host a conference call at 5:45 a.m. Pacific Daylight Time (PDT)\ntoday, Wednesday, June 3, 2026, to discuss its fourth quarter and full fiscal\n2026 financial results. The live audio webcast will be available on the\nInvestor Relations section of MiniMed's website at investors.minimed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702869-1&h=611821454&u=https%3A%2F%2Finvestors.minimed.com%2F&a=investors.minimed.com)\n. Within 24 hours of the webcast, an archived replay will be available for a\nminimum of 12 months following the call.\n\nInvestor Presentation\nAn investor presentation providing additional information and analysis can be\nfound on the Investor Relations section of MiniMed's website at\ninvestors.minimed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702869-1&h=611821454&u=https%3A%2F%2Finvestors.minimed.com%2F&a=investors.minimed.com)\n.\n\nNon-GAAP Financial Measures\nIn addition to our financial results determined in accordance with U.S. GAAP,\nwe present in this earnings press release certain financial measures that\nfacilitate management's review of the operational performance of MiniMed and\nserve as a basis for strategic planning; however, such financial measures are\nnot presented in our financial statements prepared in accordance with U.S.\nGAAP. These financial measures are considered \"non-GAAP financial measures\"\nand are intended to supplement, and should not be considered as superior to,\nfinancial measures presented in accordance with U.S. GAAP. This includes\nOrganic Revenue Growth. We believe that non-GAAP financial measures provide\ninformation useful to investors in understanding our underlying operational\nperformance and trends and may facilitate comparisons with the performance of\nother companies in the medical technologies industry.\n\nIn particular, we believe that the use of Organic Revenue Growth is helpful to\nour investors as it is a metric used by management to assess the health of our\nbusiness and our operating performance. However, non-GAAP financial\ninformation is presented for supplemental informational purposes only, has\nlimitations as an analytical tool, and should not be considered in isolation\nor as a substitute for financial information presented in accordance with U.S.\nGAAP. In addition, other companies, including companies in our industry, may\ncalculate similarly titled non-GAAP measures differently or may use other\nmeasures to evaluate their performance, all of which could reduce the\nusefulness of our non-GAAP financial measures as tools for comparison.\n\nIn the tables included at the end of this earnings press release, a\nreconciliation is provided for each historical non-GAAP financial measure\nincluded in this release to the most directly comparable financial measure\nstated in accordance with U.S. GAAP.\n\nMiniMed calculates forward-looking Organic Revenue Growth and Adjusted EBITDA\nmargin, which are non-GAAP financial measures, based on internal forecasts\nthat omit certain amounts that would be included in GAAP financial measures.\nMiniMed does not provide a reconciliation of forward-looking Non-GAAP measures\nto the comparable GAAP measure because certain items cannot be reasonably\npredicted without reasonable effort. Such items could have a substantial\nimpact on GAAP measures of financial performance.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, which are subject to\nrisks and uncertainties, including risks related to competitive factors,\ndifficulties and delays inherent in the development, manufacturing, marketing\nand sale of medical products, government regulation, geopolitical conflicts,\nchanging global trade policies, general economic conditions, and other risks\nand uncertainties described in the company's filings with the U.S. Securities\nand Exchange Commission. In some cases, you can identify these statements by\nforward-looking words or expressions, such as \"anticipate,\" \"believe,\"\n\"could,\" \"estimate,\" \"expect,\" \"forecast,\" \"intend,\" \"looking ahead,\" \"may,\"\n\"plan,\" \"possible,\" \"potential,\" \"project,\" \"should,\" \"going to,\" \"will,\" and\nsimilar words or expressions, the negative or plural of such words or\nexpressions and other comparable terminology. Actual results may differ\nmaterially from anticipated results. MiniMed does not undertake to update its\nforward-looking statements or any of the information contained in this press\nrelease, including to reflect future events or circumstances.\n\nAbout MiniMed\nMiniMed is a global leader in insulin delivery, constantly advancing therapies\nthat support people with diabetes in more than 80 countries. Our full-stack,\nintegrated ecosystem, including our insulin delivery systems, CGMs,\nalgorithms, and easy-to-use app experience, is designed to work seamlessly\ntogether, supported by white-glove, wrap-around service. For over 40 years,\nwe've pioneered therapies people can rely on by anticipating needs, reducing\nburden, and helping make life with diabetes easier. Our mission is to make\nevery day a better day for people with diabetes.\n MINIMED GROUP INC\n\nCONSOLIDATED STATEMENTS OF OPERATIONS\n\n \n\n                                                        Three months ended                                                                   Fiscal Year Ended\n\n(Unaudited)\n (in millions, except per share data)                   April 24, 2026                                April 25, 2025                         April 24, 2026                             April 25, 2025\n Net sales                                              $                837                          $                724                   $             3,102                        $             2,715\n Cost of products sold                                  357                                           319                                    1,422                                      1,187\n Gross Profit                                           480                                           405                                    1,680                                      1,528\n Operating Expenses:\n Research and development expense                       99                                            107                                    448                                        436\n Selling, general, and administrative expense           299                                           276                                    1,183                                      1,080\n Certain litigation charges, net                        5                                             165                                    16                                         165\n Other operating (income) expense, net                  168                                           4                                      221                                        (8)\n Operating loss                                         (91)                                          (148)                                  (188)                                      (146)\n Other non-operating income, net                        (1)                                           —                                      (1)                                        1\n Income before income taxes                             (90)                                          (148)                                  (187)                                      (147)\n Income tax provision                                   93                                            21                                     128                                        52\n Net loss                                               $              (183)                          $              (168)                   $              (315)                       $              (198)\n Net income attributable to noncontrolling interests    —                                             (5)                                    (16)                                       (15)\n Net loss attributable to the Company                   $              (183)                          $              (172)                   $              (331)                       $              (213)\n Basic and diluted loss per share                       $             (0.68)                          $             (0.68)                   $             (1.29)                       $             (0.84)\n Basic and diluted weighted average shares outstanding  268.1                                         252.8                                  256.6                                      252.8\n\n The data in the schedule above has been intentionally rounded to the nearest\n million.\n\n \n MINIMED GROUP INC\n\nWORLDWIDE REVENUE((1))\n\n(Unaudited)\n\n                FOURTH QUARTER                                                                                           YEAR-TO-DATE\n (in millions)  FY26                                        FY25                                             Growth      FY26                                        FY25                                        Growth\n Pumps          $                 146                            $                 154                       (5.5) %     $                 546                       $                 541                       1.0 %\n Consumables    249                                              223                                         11.7 %      956                                         854                                         11.8 %\n CGM            420                                              345                                         21.6 %      1,553                                       1,313                                       18.2 %\n Other((2))     22                                               2                                           NM          46                                          6                                           NM\n Total          $                 837                            $                 724                       15.6 %      $              3,102                        $              2,715                        14.2 %\n\n (1)  The data in this schedule has been intentionally rounded to the nearest\n      million and, therefore, may not sum. Percentages have been calculated using\n      actual, non-rounded figures and, therefore, may not recalculate precisely.\n (2)  Primarily includes net sales generated from the sales of smart insulin pens\n      and services. Amounts in this line also reflect adjustments to the Company's\n      Italian payback accruals resulting from two rulings in 2024 by the\n      Constitutional Court of Italy and the Legislative Decree published by the\n      Italian government on June 30, 2025 for certain prior years since 2015. For\n      the three months ended April 24, 2026 and April 25, 2025, there were no\n      adjustments to the Italian payback accruals. For the full year ended April 24,\n      2026 and April 25, 2025, adjustments to the Italian payback accruals were $7\n      million and ($20) million, respectively.\n\nMINIMED GROUP INC\nGAAP TO NON-GAAP RECONCILIATIONS\n\nThe data in the following schedules have been intentionally rounded to the\nnearest million and, therefore, may not sum. Percentages have been calculated\nusing actual, non-rounded figures and, therefore, may not recalculate\nprecisely.\n Organic Revenue Growth((1))\n\n                     Three Months Ended\n                     Reported net sales                                                                         Adjustments                                                                             Organic Revenue\n (in millions)       April 24, 2026                         April 25, 2025                         Growth       April 24, 2026((3))                          April 25, 2025                             April 24, 2026((3))                      April 25, 2025                         Growth\n U.S.((2))           $              238                     $              234                     1.5 %        $                 —                          $                 —                        $               238                      $              234                     1.5 %\n International((2))  599                                    489                                    22.4 %       50                                           —                                          549                                      489                                    12.2 %\n Total               $              837                     $              724                     15.6 %       $                 50                         $                 —                        $               787                      $              724                     8.7 %\n\n (1)  Organic Revenue Growth measures revenue growth trends excluding the impacts of\n      foreign currency rate fluctuations and adjustments to MiniMed's Italian\n      payback accrual for certain prior years since 2015. We use Organic Revenue\n      Growth to assess our performance on a consistent basis by removing the impacts\n      of foreign currency rate fluctuations and adjustments to the Italian payback\n      accrual that we believe do not directly reflect our underlying operations.\n (2)  U.S. includes the United States and U.S. territories. International includes\n      all other non-U.S. countries.\n (3)  The three months ended April 24, 2026 excludes $50 million of revenue\n      adjustments related to favorable currency impact on net sales. The currency\n      impact to net sales measures the change in net sales between current and prior\n      year periods using constant exchange rates.\n\n \n                     Fiscal Year Ended\n                     Reported net sales                                                                         Adjustments                                                                                 Organic Revenue\n (in millions)       April 24, 2026                         April 25, 2025                         Growth       April 24, 2026((2))                            April 25, 2025((3))                          April 24, 2026((2))                        April 25, 2025((3))                        Growth\n U.S.((1))           $              917                     $              903                     1.5 %        $                  —                           $                  —                         $                917                       $                903                       1.5 %\n International((1))  2,185                                  1,812                                  20.6 %       147                                            (20)                                         2,038                                      1,832                                      11.2 %\n Total               $           3,102                      $           2,715                      14.2 %       $                147                           $                (20)                        $            2,955                         $            2,735                         8.0 %\n\n (1)  U.S. includes the United States and U.S. territories. International includes\n      all other non-U.S. countries.\n (2)  The fiscal year ended April 24, 2026 excludes $147 million of revenue\n      adjustments, including a $7 million sales benefit from the reduction in the\n      Italian payback accruals in the first quarter of fiscal year 2026 due to\n      changes in estimates as a result of the Legislative Decree published by the\n      Italian government on June 30, 2025 for years 2015 to 2018 and $140 million of\n      favorable currency impact on the remaining net sales. The currency impact to\n      net sales measures the change in net sales between current and prior year\n      periods using constant exchange rates.\n (3)  The fiscal year ended April 25, 2025 excludes $20 million of Italian payback\n      accruals as a result of the two July 22, 2024 rulings by the Constitutional\n      Court of Italy for certain prior years since 2015.\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/minimed-delivers-strong-fourth-quarter-and-full-fiscal-year-2026-financial-results-provides-fiscal-year-2027-outlook-302789603.html\n(https://www.prnewswire.com/news-releases/minimed-delivers-strong-fourth-quarter-and-full-fiscal-year-2026-financial-results-provides-fiscal-year-2027-outlook-302789603.html)\n\nSOURCE MiniMed\n\n\n\nRyan Weispfenning, Investor Relations, +1-763-505-4626; Janet Cho, Public Relations, +1-818-403-7028\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3tqsrDa","title":"MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook","author":"PR Newswire","ticker":"MMED","created":"2026-06-03T10:46:00.047Z","tickers":["MMED"],"exchange":"NASDAQ","article_body":"MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook\n\nPR Newswire\n\nNORTHRIDGE, Calif., June 3, 2026\n\n * Continued momentum in Q4, with net sales of $837 million growing 16% as\nreported and 9% organic year-over-year\n * Record annual net sales performance surpasses $3B for first time, growing 14%\nas reported and 8% organic\n * Advanced global pipeline ahead of schedule with FDA clearance for MiniMed\nFlex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDI\nNORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a\nglobal leader in diabetes technology, today reported financial results for its\nfourth quarter and full fiscal year ended April 24, 2026.\n\n(https://mma.prnewswire.com/media/2993964/MiniMed_Earnings_Presentation_FY26Q4.pdf?p=original)\n\n\"MiniMed delivered a strong finish to our fiscal year, driven by strength in\ninternational markets and continued global adoption of the MiniMed™ 780G\nsystem,\" said MiniMed Chief Executive Officer Que Dallara. \"Looking ahead,\nwe're confident that our launches of MiniMed Flex™ and MiniMed Go™ will\nsupport long-term growth acceleration and value creation.\"\n\nFiscal Fourth Quarter Results\n\n * Continued momentum through the second half of the fiscal year 2026, driven by\nSimplera™ and Instinct sensor, made by Abbott, CGM launches\n * Worldwide net sales of $837 million grew 15.6% as reported and 8.7% organic\n* International net sales of $599 million grew 22.4% as reported and 12.2%\norganic, driven by Simplera capacity expansion; International New Pumps Sold\n(NPS) increased high-single digits sequentially\n * U.S. net sales of $238 million grew 1.5% as reported and organic, as early FDA\nclearance of MiniMed™ Flex shifted demand of customers who preferred to\nwait for the new system. Flex is on track to launch this month. U.S. momentum\ncontinued with NPS increasing mid-single digits sequentially driven by new\nsensor launches\n * Worldwide NPS of ~42,000, an increase of 7.4% quarter-over-quarter\n * Worldwide CGM Attachment Rate of 68%, an increase of 100 bps\nquarter-over-quarter\nFiscal Year 2026 Results\n\n * Worldwide net sales of $3.102 billion grew 14.2% as reported and 8.0% organic\n* International net sales of $2.185 billion grew 20.6% as reported and 11.2%\norganic\n * U.S. net sales of $917 million grew 1.5% as reported and organic\n * Worldwide New Pumps Sold of ~145,000 were unchanged year-over-year\n * Worldwide CGM Attachment Rate of 66%, an increase of 700 bps year-over-year\n * Ended FY26 with worldwide pump users of ~659,000\nFiscal Year 2026 Highlights\n\n * Commercial launches of MiniMed™ 780G system with Instinct sensor and\nSimplera Sync™ sensor in the U.S.; MiniMed Go™ Smart MDI system in EMEA\n * U.S. FDA clearances of MiniMed Flex™ next-generation insulin pump and\nMiniMed Go™ Smart MDI system\n * CE Marks received for MiniMed™ 780G system with Instinct sensor, and\nMiniMed™ 780G system for ages 2 and older, pregnant women, and type 2\ndiabetes\n * U.S. pharmacy formulary access for MiniMed™ 780G system and Medicare access\nfor MiniMed™ 780G system with Instinct sensor\n * Started U.S. pivotal study for Vivera™ third generation fully closed loop\nalgorithm for type 1 and type 2 diabetes\nNew Announcements Made Today\n\n * U.S. MiniMed Go™ was launched last week\n * MiniMed™ 780G with Instinct will launch in Europe later this month\n * MiniMed Flex™ pre-orders in the U.S. started this week and expect to begin\nshipping later this month\n * Extension today to Abbott partnership to commercialize dual glucose-ketone\nsensors designed to integrate exclusively with our MiniMed smart dosing\nsystems\nFiscal Year 2027 Outlook\nFor the fiscal year 2027 ending April 30, 2027, MiniMed expects:\n\n * Organic revenue growth of approximately 10%, which includes a 1.0 to 1.5%\nexpected benefit from the extra week in FY27.\n * Adjusted EBITDA margin of approximately 16%.\nConference Call Details\nMiniMed will host a conference call at 5:45 a.m. Pacific Daylight Time (PDT)\ntoday, Wednesday, June 3, 2026, to discuss its fourth quarter and full fiscal\n2026 financial results. The live audio webcast will be available on the\nInvestor Relations section of MiniMed's website at investors.minimed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702869-1&h=611821454&u=https%3A%2F%2Finvestors.minimed.com%2F&a=investors.minimed.com)\n. Within 24 hours of the webcast, an archived replay will be available for a\nminimum of 12 months following the call.\n\nInvestor Presentation\nAn investor presentation providing additional information and analysis can be\nfound on the Investor Relations section of MiniMed's website at\ninvestors.minimed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702869-1&h=611821454&u=https%3A%2F%2Finvestors.minimed.com%2F&a=investors.minimed.com)\n.\n\nNon-GAAP Financial Measures\nIn addition to our financial results determined in accordance with U.S. GAAP,\nwe present in this earnings press release certain financial measures that\nfacilitate management's review of the operational performance of MiniMed and\nserve as a basis for strategic planning; however, such financial measures are\nnot presented in our financial statements prepared in accordance with U.S.\nGAAP. These financial measures are considered \"non-GAAP financial measures\"\nand are intended to supplement, and should not be considered as superior to,\nfinancial measures presented in accordance with U.S. GAAP. This includes\nOrganic Revenue Growth. We believe that non-GAAP financial measures provide\ninformation useful to investors in understanding our underlying operational\nperformance and trends and may facilitate comparisons with the performance of\nother companies in the medical technologies industry.\n\nIn particular, we believe that the use of Organic Revenue Growth is helpful to\nour investors as it is a metric used by management to assess the health of our\nbusiness and our operating performance. However, non-GAAP financial\ninformation is presented for supplemental informational purposes only, has\nlimitations as an analytical tool, and should not be considered in isolation\nor as a substitute for financial information presented in accordance with U.S.\nGAAP. In addition, other companies, including companies in our industry, may\ncalculate similarly titled non-GAAP measures differently or may use other\nmeasures to evaluate their performance, all of which could reduce the\nusefulness of our non-GAAP financial measures as tools for comparison.\n\nIn the tables included at the end of this earnings press release, a\nreconciliation is provided for each historical non-GAAP financial measure\nincluded in this release to the most directly comparable financial measure\nstated in accordance with U.S. GAAP.\n\nMiniMed calculates forward-looking Organic Revenue Growth and Adjusted EBITDA\nmargin, which are non-GAAP financial measures, based on internal forecasts\nthat omit certain amounts that would be included in GAAP financial measures.\nMiniMed does not provide a reconciliation of forward-looking Non-GAAP measures\nto the comparable GAAP measure because certain items cannot be reasonably\npredicted without reasonable effort. Such items could have a substantial\nimpact on GAAP measures of financial performance.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, which are subject to\nrisks and uncertainties, including risks related to competitive factors,\ndifficulties and delays inherent in the development, manufacturing, marketing\nand sale of medical products, government regulation, geopolitical conflicts,\nchanging global trade policies, general economic conditions, and other risks\nand uncertainties described in the company's filings with the U.S. Securities\nand Exchange Commission. In some cases, you can identify these statements by\nforward-looking words or expressions, such as \"anticipate,\" \"believe,\"\n\"could,\" \"estimate,\" \"expect,\" \"forecast,\" \"intend,\" \"looking ahead,\" \"may,\"\n\"plan,\" \"possible,\" \"potential,\" \"project,\" \"should,\" \"going to,\" \"will,\" and\nsimilar words or expressions, the negative or plural of such words or\nexpressions and other comparable terminology. Actual results may differ\nmaterially from anticipated results. MiniMed does not undertake to update its\nforward-looking statements or any of the information contained in this press\nrelease, including to reflect future events or circumstances.\n\nAbout MiniMed\nMiniMed is a global leader in insulin delivery, constantly advancing therapies\nthat support people with diabetes in more than 80 countries. Our full-stack,\nintegrated ecosystem, including our insulin delivery systems, CGMs,\nalgorithms, and easy-to-use app experience, is designed to work seamlessly\ntogether, supported by white-glove, wrap-around service. For over 40 years,\nwe've pioneered therapies people can rely on by anticipating needs, reducing\nburden, and helping make life with diabetes easier. Our mission is to make\nevery day a better day for people with diabetes.\n MINIMED GROUP INC\n\nCONSOLIDATED STATEMENTS OF OPERATIONS\n\n \n\n                                                        Three months ended                                                                   Fiscal Year Ended\n\n(Unaudited)\n (in millions, except per share data)                   April 24, 2026                                April 25, 2025                         April 24, 2026                             April 25, 2025\n Net sales                                              $                837                          $                724                   $             3,102                        $             2,715\n Cost of products sold                                  357                                           319                                    1,422                                      1,187\n Gross Profit                                           480                                           405                                    1,680                                      1,528\n Operating Expenses:\n Research and development expense                       99                                            107                                    448                                        436\n Selling, general, and administrative expense           299                                           276                                    1,183                                      1,080\n Certain litigation charges, net                        5                                             165                                    16                                         165\n Other operating (income) expense, net                  168                                           4                                      221                                        (8)\n Operating loss                                         (91)                                          (148)                                  (188)                                      (146)\n Other non-operating income, net                        (1)                                           —                                      (1)                                        1\n Income before income taxes                             (90)                                          (148)                                  (187)                                      (147)\n Income tax provision                                   93                                            21                                     128                                        52\n Net loss                                               $              (183)                          $              (168)                   $              (315)                       $              (198)\n Net income attributable to noncontrolling interests    —                                             (5)                                    (16)                                       (15)\n Net loss attributable to the Company                   $              (183)                          $              (172)                   $              (331)                       $              (213)\n Basic and diluted loss per share                       $             (0.68)                          $             (0.68)                   $             (1.29)                       $             (0.84)\n Basic and diluted weighted average shares outstanding  268.1                                         252.8                                  256.6                                      252.8\n\n The data in the schedule above has been intentionally rounded to the nearest\n million.\n\n \n MINIMED GROUP INC\n\nWORLDWIDE REVENUE((1))\n\n(Unaudited)\n\n                FOURTH QUARTER                                                                                           YEAR-TO-DATE\n (in millions)  FY26                                        FY25                                             Growth      FY26                                        FY25                                        Growth\n Pumps          $                 146                            $                 154                       (5.5) %     $                 546                       $                 541                       1.0 %\n Consumables    249                                              223                                         11.7 %      956                                         854                                         11.8 %\n CGM            420                                              345                                         21.6 %      1,553                                       1,313                                       18.2 %\n Other((2))     22                                               2                                           NM          46                                          6                                           NM\n Total          $                 837                            $                 724                       15.6 %      $              3,102                        $              2,715                        14.2 %\n\n (1)  The data in this schedule has been intentionally rounded to the nearest\n      million and, therefore, may not sum. Percentages have been calculated using\n      actual, non-rounded figures and, therefore, may not recalculate precisely.\n (2)  Primarily includes net sales generated from the sales of smart insulin pens\n      and services. Amounts in this line also reflect adjustments to the Company's\n      Italian payback accruals resulting from two rulings in 2024 by the\n      Constitutional Court of Italy and the Legislative Decree published by the\n      Italian government on June 30, 2025 for certain prior years since 2015. For\n      the three months ended April 24, 2026 and April 25, 2025, there were no\n      adjustments to the Italian payback accruals. For the full year ended April 24,\n      2026 and April 25, 2025, adjustments to the Italian payback accruals were $7\n      million and ($20) million, respectively.\n\nMINIMED GROUP INC\nGAAP TO NON-GAAP RECONCILIATIONS\n\nThe data in the following schedules have been intentionally rounded to the\nnearest million and, therefore, may not sum. Percentages have been calculated\nusing actual, non-rounded figures and, therefore, may not recalculate\nprecisely.\n Organic Revenue Growth((1))\n\n                     Three Months Ended\n                     Reported net sales                                                                         Adjustments                                                                             Organic Revenue\n (in millions)       April 24, 2026                         April 25, 2025                         Growth       April 24, 2026((3))                          April 25, 2025                             April 24, 2026((3))                      April 25, 2025                         Growth\n U.S.((2))           $              238                     $              234                     1.5 %        $                 —                          $                 —                        $               238                      $              234                     1.5 %\n International((2))  599                                    489                                    22.4 %       50                                           —                                          549                                      489                                    12.2 %\n Total               $              837                     $              724                     15.6 %       $                 50                         $                 —                        $               787                      $              724                     8.7 %\n\n (1)  Organic Revenue Growth measures revenue growth trends excluding the impacts of\n      foreign currency rate fluctuations and adjustments to MiniMed's Italian\n      payback accrual for certain prior years since 2015. We use Organic Revenue\n      Growth to assess our performance on a consistent basis by removing the impacts\n      of foreign currency rate fluctuations and adjustments to the Italian payback\n      accrual that we believe do not directly reflect our underlying operations.\n (2)  U.S. includes the United States and U.S. territories. International includes\n      all other non-U.S. countries.\n (3)  The three months ended April 24, 2026 excludes $50 million of revenue\n      adjustments related to favorable currency impact on net sales. The currency\n      impact to net sales measures the change in net sales between current and prior\n      year periods using constant exchange rates.\n\n \n                     Fiscal Year Ended\n                     Reported net sales                                                                         Adjustments                                                                                 Organic Revenue\n (in millions)       April 24, 2026                         April 25, 2025                         Growth       April 24, 2026((2))                            April 25, 2025((3))                          April 24, 2026((2))                        April 25, 2025((3))                        Growth\n U.S.((1))           $              917                     $              903                     1.5 %        $                  —                           $                  —                         $                917                       $                903                       1.5 %\n International((1))  2,185                                  1,812                                  20.6 %       147                                            (20)                                         2,038                                      1,832                                      11.2 %\n Total               $           3,102                      $           2,715                      14.2 %       $                147                           $                (20)                        $            2,955                         $            2,735                         8.0 %\n\n (1)  U.S. includes the United States and U.S. territories. International includes\n      all other non-U.S. countries.\n (2)  The fiscal year ended April 24, 2026 excludes $147 million of revenue\n      adjustments, including a $7 million sales benefit from the reduction in the\n      Italian payback accruals in the first quarter of fiscal year 2026 due to\n      changes in estimates as a result of the Legislative Decree published by the\n      Italian government on June 30, 2025 for years 2015 to 2018 and $140 million of\n      favorable currency impact on the remaining net sales. The currency impact to\n      net sales measures the change in net sales between current and prior year\n      periods using constant exchange rates.\n (3)  The fiscal year ended April 25, 2025 excludes $20 million of Italian payback\n      accruals as a result of the two July 22, 2024 rulings by the Constitutional\n      Court of Italy for certain prior years since 2015.\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/minimed-delivers-strong-fourth-quarter-and-full-fiscal-year-2026-financial-results-provides-fiscal-year-2027-outlook-302789603.html\n(https://www.prnewswire.com/news-releases/minimed-delivers-strong-fourth-quarter-and-full-fiscal-year-2026-financial-results-provides-fiscal-year-2027-outlook-302789603.html)\n\nSOURCE MiniMed\n\n\n\nRyan Weispfenning, Investor Relations, +1-763-505-4626; Janet Cho, Public Relations, +1-818-403-7028\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-03T10:46:00.110206641Z","server_sent_at_ms":1780483560110},"received_at":"2026-06-03T10:46:00.269Z","source_url":"https://www.prnewswire.com/news-releases/minimed-delivers-strong-fourth-quarter-and-full-fiscal-year-2026-financial-results-provides-fiscal-year-2027-outlook-302789603.html"},"analysis":{"id":"42797","press_release_id":"53366","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"MiniMed reported record full-year 2026 net sales of $3.10 billion, up 14% as reported and 8% organically, driven by strong international growth and new product adoption.\n\nQ4 net sales reached $837 million, with international sales growing 22% as reported and 12% organically, while U.S. sales grew 1.5% as demand shifted toward the upcoming launch of the MiniMed Flex system.\n\nThe company guided for approximately 10% organic revenue growth in FY27 and an adjusted EBITDA margin of 16%, supported by the global rollout of MiniMed Flex and MiniMed Go, and an extended partnership with Abbott for dual glucose-ketone sensors.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"MiniMed crosses $3B revenue milestone with strong international momentum; new product launches (Flex/Go) set to drive FY27 growth."},"keyFigures":{"revenue":3102000000,"guidance":"FY27 organic revenue growth ~10% (including 1.0-1.5% benefit from extra week); Adjusted EBITDA margin ~16%","revenueYoy":"14.2%","customDimensions":{"q4_revenue":837000000,"fy26_net_loss":331000000,"fy26_us_revenue":917000000,"total_pump_users":659000,"fy26_gross_profit":1680000000,"q4_new_pumps_sold":42000,"fy26_new_pumps_sold":145000,"q4_cgm_attachment_rate":"68%","q4_revenue_yoy_organic":"8.7%","q4_revenue_yoy_reported":"15.6%","fy26_cgm_attachment_rate":"66%","fy26_international_revenue":2185000000}},"quotedText":"MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets and continued global adoption of the MiniMed™ 780G system","namedEntities":{"people":[{"name":"Que Dallara","role":"CEO"},{"name":"Ryan Weispfenning","role":"Investor Relations"},{"name":"Janet Cho","role":"Public Relations"}],"products":["MiniMed 780G","MiniMed Flex","MiniMed Go","Instinct sensor","Simplera Sync sensor","Vivera"],"companies":[{"name":"MiniMed","ticker":"MMED"},{"name":"Abbott","relationship":"partner"}],"dollarAmounts":[{"amount":"$837 million","context":"Q4 net sales"},{"amount":"$3.102 billion","context":"Full fiscal year 2026 net sales"},{"amount":"$599 million","context":"Q4 international net sales"},{"amount":"$238 million","context":"Q4 U.S. net sales"},{"amount":"$2.185 billion","context":"FY26 international net sales"},{"amount":"$917 million","context":"FY26 U.S. net sales"},{"amount":"$1,680 million","context":"FY26 gross profit"},{"amount":"$331 million","context":"FY26 net loss attributable to the Company"},{"amount":"$50 million","context":"Q4 revenue adjustment for favorable currency impact"},{"amount":"$147 million","context":"FY26 revenue adjustment (currency + Italian payback)"}]},"materialImpact":{"score":4,"reasoning":"MiniMed reported record annual net sales exceeding $3B for the first time, with 14% reported growth and 8% organic growth. The company provided FY27 guidance for ~10% organic revenue growth and 16% adjusted EBITDA margin, signaling strong momentum from new product launches (Flex, Go) and international expansion."},"tickerRelevance":{"others":[{"ticker":"ABT","relevance":"partner"}],"primary":"MMED"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":["guidance_update","product_launch"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"earnings_beat_record_revenue","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"event_type":"earnings","event_type_secondary":["guidance_update","product_launch"],"sentiment":"bullish","material_impact_score":4,"narrative":"MiniMed reported record full-year 2026 net sales of $3.10 billion, up 14% as reported and 8% organically, driven by strong international growth and new product adoption.\n\nQ4 net sales reached $837 million, with international sales growing 22% as reported and 12% organically, while U.S. sales grew 1.5% as demand shifted toward the upcoming launch of the MiniMed Flex system.\n\nThe company guided for approximately 10% organic revenue growth in FY27 and an adjusted EBITDA margin of 16%, supported by the global rollout of MiniMed Flex and MiniMed Go, and an extended partnership with Abbott for dual glucose-ketone sensors.","key_figures":{"revenue":3102000000,"guidance":"FY27 organic revenue growth ~10% (including 1.0-1.5% benefit from extra week); Adjusted EBITDA margin ~16%","revenueYoy":"14.2%","customDimensions":{"q4_revenue":837000000,"fy26_net_loss":331000000,"fy26_us_revenue":917000000,"total_pump_users":659000,"fy26_gross_profit":1680000000,"q4_new_pumps_sold":42000,"fy26_new_pumps_sold":145000,"q4_cgm_attachment_rate":"68%","q4_revenue_yoy_organic":"8.7%","q4_revenue_yoy_reported":"15.6%","fy26_cgm_attachment_rate":"66%","fy26_international_revenue":2185000000}},"named_entities":{"people":[{"name":"Que Dallara","role":"CEO"},{"name":"Ryan Weispfenning","role":"Investor Relations"},{"name":"Janet Cho","role":"Public Relations"}],"products":["MiniMed 780G","MiniMed Flex","MiniMed Go","Instinct sensor","Simplera Sync sensor","Vivera"],"companies":[{"name":"MiniMed","ticker":"MMED"},{"name":"Abbott","relationship":"partner"}],"dollarAmounts":[{"amount":"$837 million","context":"Q4 net sales"},{"amount":"$3.102 billion","context":"Full fiscal year 2026 net sales"},{"amount":"$599 million","context":"Q4 international net sales"},{"amount":"$238 million","context":"Q4 U.S. net sales"},{"amount":"$2.185 billion","context":"FY26 international net sales"},{"amount":"$917 million","context":"FY26 U.S. net sales"},{"amount":"$1,680 million","context":"FY26 gross profit"},{"amount":"$331 million","context":"FY26 net loss attributable to the Company"},{"amount":"$50 million","context":"Q4 revenue adjustment for favorable currency impact"},{"amount":"$147 million","context":"FY26 revenue adjustment (currency + Italian payback)"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-04T05:20:42.890Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap","eventGravity":"earnings_beat_record_revenue","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"durationMs":null,"modelName":"george-droid-qwen-72b"}}